Worldwide Clinical Trials to support Ph III trial for Renova Therapeutics

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/iLexx)
(Image: iStock/iLexx)

Related tags: Executive vice president, Clinical trial, Contract research organization

Worldwide Clinical Trials will support the full scope of Renova Therapeutics Phase III trial for its lead gene therapy product candidate, says the CRO.

According to Renova Therapeutics​, selecting a contract research organization (CRO) is a “key milestone​” following a completed end-of-phase II meeting with the US Food and Drug Administration (FDA) for its lead gene therapy product candidate, RT-100, last year.

David Bowser, Worldwide Clinical Trials, executive vice president and general manager for global clinical development, told us the company is currently working closely with Renova on study start up and confirming the complete study schedule, as the CRO was contracted to support the full scope of the study.

We treat all customer relationships as long-term partnerships and are appropriately staffed to manage this study. However, we’re always looking to add talented and passionate people​ to our team to help us with projects like this one​,” he added.

Worldwide Clinical Trials will work in collaboration with Renova’s Dr. Richard McCloskey, MD, executive vice president of clinical development, and Jennifer Spinella, senior vice president of regulatory affairs and quality assurance, throughout the Phase III study.

The trial is set to start in the second half of 2017, with 536 patients across 60 US-based medical centers.

Bellerophon Therapeutics

In related news, Bellerophon Therapeutics​ has announced confirmation from the FDA of its acceptance of all modifications proposed by the company to its Phase III program for INOpulse in Pulmonary Arterial Hypertension (PAH).

Worldwide Clinical Trials is Bellerophon’s strategic CRO partner for the INOpulse PAH program.

According to the CRO, it will be providing a range of services for the modified Phase III study, including regulatory affairs, site monitoring, project management, safety and medical monitoring support, and trial master file services.

The protocol changes are expected to reduce time to market for INOpulse by approximately two years.

Related topics: Clinical Development, Phase III-IV

Related news

Show more

Related products

show more

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Related suppliers

Follow us

Products

View more

Webinars